Biblioteca
All documents
Session 3 - VICH moving forwards
Restructuring (and future vision) - S. Iwamoto
VICH workplan - M. Churchill
The view of a VICH Forum member - Y. Kosenko
Session 4 - How VICH guidelines are developed, implemented and used
How VICH guidelines are developed, implemented and used - B. Boenisch
How VICH guidelines implement the 3Rs in safety studies - E. Werner
Challenges and perspectives in adopting VICH guidelines in VICH Forum countries/regions and how to overcome them - A. Ogutu
Session 5 - Scientific issues
Scientific topic 1: Safety of monoclonal antibodies - C. Stirling
Scientific topic 2: Pharmacovigilance and signal management - K. Schirmann
Scientific topic 3:– bioequivalence and dissolution testing - M. Martinez
Session 6 - New or revised VICH GLs
GL topic 1: anthelmintics - A. Phillippi-Taylor
GL topic 2: Good manufacturing practice for active pharmaceutical ingredients - M. Huynh
GL topic 3: pharmaceutical development - M. Huynh
Session 7 - Opportunities from international guidelines and regional collaborations
International collaborations - M. Bassi
GMP Inspections Reliance Programmes and Mutual Recognition Agreements - G. Verdier & P. Krauze
Regional collaboration and mutual reliance - I. Ravengai
Session 8 - Technical challenges
New science in veterinary biologics - K. Sato
New science and reduction in the use of experimental animals - S. Adler-Flindt
Real world evidence and big data - R. Carapeto
Session 9 - The future
The expectations from a VICH Forum member - B. Borges Cordeiro
Inspired by VICH: International Forum on in vitro diagnostics - J. Essolomwa
Supported by VICH: Regulatory convergence - C. du Marchie Sarvaas
The Vision for the future - I. Claassen
43rd VICH Steering Committee & 17th VF meetings, November 10-15, 2024
Public Statement (15 November 2024)